MMAI

5-Methoxy-6-methyl-2-aminoindane (MMAI) is a drug of the 2-aminoindane family developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a less neurotoxic and highly selective serotonin releasing agent (SSRA) and produces entactogenic effects in humans. The drug has been sold as a designer drug and research chemical online since 2010.
Wikipedia contributors, "MMAI", Wikipedia, revision 1373753670, retrieved 20 November 2026, source, CC BY-SA 4.0.